YHO-13351

SKU: orb1708202

Description

YHO-13351 is an acrylonitrile-based ABCG2 inhibitor that sensitizes cancer stem-like side population cells to irinotecan. GSK1702934A is a research tool for studying diabetes, including investigations into TRPC channel function in pancreatic beta-cells in vitro.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 1346753-00-1
• MW: 579.73
• Purity: 97.98% (May vary between batches)
• Formula: C₂₇H₃₇N₃O₇S₂
• SMILES: S(C)(=O)(=O)O.C(=C(\C#N)/C1=CC(OC)=C(OC)C=C1)\C=2SC(=CC2)N3CCC(OC(CN(CC)CC)=O)CC3
• Target: ABC Transporter,BCRP
• Solubility: DMSO:160 mg/mL (275.99 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (8.62 mM)

Bioactivity

• In Vivo:
  When used in combination with irinotecan, YHO-13351 reduces the increase in the ratio of SP cells in tumors compared to treatment with irinotecan alone.
• In Vitro:
  In the presence of YHO-13351 (0-0.1 μM), HeLa cells stained with Hoechst dye were analyzed by flow cytometry using a fluorescence-activated cell sorter, which revealed that YHO-13177 is capable of reducing the SP fraction score .

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

YHO 13351, YHO13351, YHO-13351, ABCG2

Compound Identifiers

PubChem CID

53344604